Fezolinetant- A novel NK3R antagonist for treating postmenopausal vasomotor symptoms
Madam, It has been estimated that up to 80% of postmenopausal women experience vasomotor symptoms (VMS) such as hot flushes, night sweats, mood swings and difficulty in concentrating1. These symptoms markedly affect different aspects of daily life for women, including, sleep, mental well-being, s...
Saved in:
| Main Authors: | Saqib Ali, Muhammad Affan Ilyas |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pakistan Medical Association
2024-07-01
|
| Series: | Journal of the Pakistan Medical Association |
| Online Access: | https://jpma.org.pk/index.php/public_html/article/view/20096 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting vasomotor symptoms with the new drug fezolinetant – an expert overview
by: Rossella E. Nappi, et al.
Published: (2025-12-01) -
Fezolinetant’s efficacy and safety in treatment of vasomotor symptoms in postmenopausal women: a meta-analysis and GRADE evaluation of randomized controlled trials
by: Abdallah R. Allam, et al.
Published: (2025-01-01) -
Efficacy and safety of fezolinetant and its different doses in the treatment of vasomotor symptoms in menopausal women: a systematic review and meta-analysis
by: Rahma Abdelaziz Ismail, et al.
Published: (2025-06-01) -
Prevalence, severity, and association of serum follicle-stimulating hormone level with vasomotor and genitourinary symptoms in perimenopausal and postmenopausal women
by: Priya Saini, et al.
Published: (2025-07-01) -
Characterization and Treatment Patterns of Peri/Menopausal and Postmenopausal Women with and Without Vasomotor Symptoms in a Retrospective Database Study
by: Lena Charafi, et al.
Published: (2025-01-01)